- Home
- Clinical Trials
Peanut Allergy Studies Auckland
PUFFIN Peanut Allergy Study
Auckland
We are looking for people aged 18-55 years with a physician-diagnosed peanut allergy to participate in the Puffin study, which is investigating a potential new trial medication designed to reduce allergic reactions while promoting protective immune responses.
Description
What to expect
Study details
Ages
Adults aged 18-55 years old
Duration
10-12 clinic visits over 5-9 months
Compensation
Up to $5,937 (pre-tax)
Eligibility Criteria
- Adults aged 18-55 years old
- Doctor-diagnosed peanut allergy
- In otherwise good general health (apart from peanut allergy)
- Non-smoker or occasional smoker
- Willing to avoid peanuts during study
Locations
Description
The study drug is a new investigational medication being developed for people with peanut allergy.
It’s an mRNA-based therapy similar in technology to some COVID-19 vaccines; however, instead of protecting against a virus, it’s designed to help your immune system react differently to peanut proteins.
People with peanut allergies have immune systems that overreact to certain peanut proteins (called Ara h1 and Ara h2). This overreaction causes the release of chemicals like histamine, which lead to allergic symptoms from hives to serious reactions like anaphylaxis.
The study drug contains messenger RNA (mRNA) that instructs the body’s cells to make modified, “safer” versions of the same peanut proteins. These modified proteins:
- Do not cause an allergic reaction like real peanut exposure would
- Help the immune system learn to tolerate peanut proteins gradually
- May shift the immune response away from allergy-triggering IgE antibodies toward more protective IgG antibodies
You can think of it like “immune training”. Instead of avoiding peanuts completely, this approach carefully “teaches” the immune system to stop overreacting.
What to expect
Reason to participate
Your involvement in this study may help advance scientific knowledge that could contribute to the development of a new medication and better treatment for people with peanut allergies in the future. Other reasons to participate may include:
- Help advance research towards the first mRNA-based trial medication for peanut allergy
- Receive study-related medical care and monitoring at no cost
- Contribute to a trial medication that could improve the quality of life for people living with food allergies
Participants will attend around 10–12 visits over 5–9 months, including:
- 1–3 screening visits
- 3 trial medication treatment visits
- Food challenges before and after trial medication administration
- Several follow-up and monitoring visits
During visits, we conduct health checks that may include physical examinations and blood tests. We would like to ask you questions about your peanut allergy and your general health. Other procedures throughout the study include:
- Medical history review
- Vital signs and health checks
- Review of peanut allergy history and prior reactions
- Skin prick test (SPT) to confirm peanut allergy
- Routine safety bloodwork (haematology, chemistry, urinalysis)
- ECGs (electrocardiogram)
- Pregnancy test (if applicable)
- Screening food challenge
- 3 intramuscular injections of study medication
All participants will receive the active study drug; placebo is used only in the food challenge meals, not as a trial medication treatment arm.
The study medication is administered 3 times throughout the study as an intramuscular (IM) injection in the upper arm. The medication is administered at the clinic by trained clinical staff. There is one overnight stay after the first injection for safety monitoring.
The study aims to investigate the study medication at different dosages and intervals to evaluate its safety, tolerability and efficacy in reducing peanut allergy reactions.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
Momentum Clinical Research NZ is a member of the Global Site Holdings Group. Global Site Holdings Pty Limited ACN 668 977 062 trading as Momentum Clinical Research ABN 51 668 977 062 and our related entities (we, us, our), will use the Personal Information you have provided in the above form to review and respond to your enquiry, to contact you about any future trials or studies you may be eligible for, and otherwise in accordance with our Privacy Policy and as required and authorised by law. We may not be able to provide you with a complete response or a response at all to your enquiry if you do not provide the requested information. Our Privacy Policy also contains further information about how we collect, use, store or disclose your Personal Information, how you may seek access and correction of your Personal Information, and how you may make a complaint about a breach of privacy. If you have questions, please contact us at contact@momentumclinicalresearch.com.